UNSPSC 51451608: Dribendazole

This classification denotes an antihelminthic agent with the molecular formula C15H19N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5491IVP21O, chemically known as carbamic acid, (5-(cyclohexylthio)-1h-benzimidazol-2-yl)-,methyl ester but generally known as dribendazole, which bears US NIH Compound Identifier 170311. European Medicines Agency schedules Dribendazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06399MIG.

UNSPSC 51451608 Dribendazole is a Commodity code for a specific anthelmintic pharmaceutical product, but the recent state and local contract opportunities tagged under it do not reflect procurement of dribendazole itself. Instead, the opportunities on record show state and local health agencies sourcing other pharmaceutical products — antibiotic tablets, naloxone, and drug deactivation systems — through competitive procurement vehicles. The mismatch suggests either tagging inconsistency in the source data or that dribendazole procurement, if it occurs, is not appearing in the tracked state and local opportunities at this time. State and local buyers under this code include state health departments and county health authorities purchasing pharmaceuticals through piggyback cooperative purchasing arrangements and direct IFB processes.

The geographic activity centers on Illinois and Florida, with the Illinois Department of Public Health having awarded a pharmaceutical piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for $2,999,999.11 over three years (12-month initial term with two renewal options), and Seminole County, Florida posting an IFB for naloxone and drug deactivation systems with a due date of July 26, 2023, requiring quarterly deliveries to the Seminole County Community Health Building in Sanford. The Illinois transaction was a completed award through an IFB process, not an open solicitation. The code shows limited recent activity specifically aligned with dribendazole procurement; firms should verify whether opportunities tagged under this code actually reflect dribendazole demand or represent data-quality issues in the source system before committing significant business development resources.